Renal Cell Carcinoma Drug Market Will More than Double Over the Next Decade, Rising from $625 Million in 2007 to Nearly $1.6 Billion in 2017
According to the new Pharmacor report entitled Renal Cell Carcinoma,Sutent will maintain its position as the leading therapy for the disease andwill capture $841 million in sales in 2017 in the United States, France,Germany, Italy, Spain, United Kingdom and Japan. The report finds thatmultikinase inhibitors, which comprised 92 percent of the renal cell carcinomadrug market in 2007, will capture nearly three quarters of the market in 2017.
The report also finds that three emerging targeted therapies-GlaxoSmithKline's Armala, Pfizer's axitinib and Novartis's everolimus-willlaunch over the next decade and will achieve significant uptake in the second-line patient segment through 2017. Additionally, although there are notreatments that have, to date, shown efficacy in the adjuvant setting innonmetastatic renal cell carcinoma patients, the results of clinical trialsunderway in this patient segment could further drive market growth.
"The most notable trial currently underway, the Adjuvant Sorafenib orSunitinib in Unfavorable Renal Cell Carcinoma trial, is comparing the efficacyof Sutent versus Bayer Healthcare/Onyx's Nexavar versus placebo in extendingdisease-free survival in the adjuvant setting," said Ramya Kollipara, Ph.D.,analyst at Decision Resources. "If these drugs are approved for treatment inthe adjuvant setting, their use in this setting will be a major driver ofgrowth in the renal cell carcinoma market over the next decade."
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in marketresearch publications, advisory services, and consulting designed to helpclients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE Decision Resources
You May Also Like